In recent news related to Zoetis, various financial institutions shifted their holdings. Citigroup and Mizuho Securities USA LLC decreased their stakes, while others like Charles Schwab Investment Management Inc. and King Luther Capital Management Corp increased positions. Zoetis reported strong Q3 2024 earnings, beating Wall Street's estimates, and impressive revenue growth. The company has also raised its 2024 outlook after these earnings results. Zoetis leadership undergoes changes with a new CCO role created. The company also authorized a multi-year $6 Billion Share Repurchase Program. Also, the company acquired Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products from Phibro Animal Health Corporation. An innovative product, Vetscan OptiCell, was unveiled with potential for market growth. However, Zoetis' stock has experienced some concern over fluctuations and impacts from arthritis drugs on pets.
Zoetis ZTS News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 23 Nov 2024 11:21:18 GMT - Rating 6 - Innovation 8 - Information 8 - Rumor 4
